Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases.
Tonacio AC, do Nascimento Pedrosa T, Borba EF, Aikawa NE, Pasoto SG, Filho JCRF, Sampaio Barros MM, Leon EP, Lombardi SCFS, Junior AM, Azevedo AS, Schwarcz WD, Fuller R, Yuki EFN, Ugolini Lopes MR, Rodrigues Pereira RM, Sampaio Barros PD, de Andrade DCO, de Medeiros-Ribeiro AC, de Moraes JCB, Shinjo SK, Miossi R, da Silva Duarte AJ, Lopes MH, Kallás EG, Almeida da Silva CA, Bonfá E. Tonacio AC, et al. Among authors: kallas eg. PLoS Negl Trop Dis. 2021 Nov 29;15(11):e0010002. doi: 10.1371/journal.pntd.0010002. eCollection 2021 Nov. PLoS Negl Trop Dis. 2021. PMID: 34843469 Free PMC article. Clinical Trial.
CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients.
Avelino-Silva VI, Miyaji KT, Mathias A, Costa DA, de Carvalho Dias JZ, Lima SB, Simoes M, Freire MS, Caiaffa-Filho HH, Hong MA, Lopes MH, Sartori AM, Kallas EG. Avelino-Silva VI, et al. Among authors: kallas eg. J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):189-95. doi: 10.1097/QAI.0000000000000845. J Acquir Immune Defic Syndr. 2016. PMID: 26361176
Predictors of mortality in patients with yellow fever: an observational cohort study.
Kallas EG, D'Elia Zanella LGFAB, Moreira CHV, Buccheri R, Diniz GBF, Castiñeiras ACP, Costa PR, Dias JZC, Marmorato MP, Song ATW, Maestri A, Borges IC, Joelsons D, Cerqueira NB, Santiago E Souza NC, Morales Claro I, Sabino EC, Levi JE, Avelino-Silva VI, Ho YL. Kallas EG, et al. Lancet Infect Dis. 2019 Jul;19(7):750-758. doi: 10.1016/S1473-3099(19)30125-2. Epub 2019 May 16. Lancet Infect Dis. 2019. PMID: 31104909
Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.
Kallas EG, Precioso AR, Palacios R, Thomé B, Braga PE, Vanni T, Campos LMA, Ferrari L, Mondini G, da Graça Salomão M, da Silva A, Espinola HM, do Prado Santos J, Santos CLS, Timenetsky MDCST, Miraglia JL, Gallina NMF, Weiskopf D, Sette A, Goulart R, Salles RT, Maestri A, Sallum AME, Farhat SCL, Sakita NK, Ferreira JCOA, Silveira CGT, Costa PR, Raw I, Whitehead SS, Durbin AP, Kalil J. Kallas EG, et al. Lancet Infect Dis. 2020 Jul;20(7):839-850. doi: 10.1016/S1473-3099(20)30023-2. Epub 2020 Mar 24. Lancet Infect Dis. 2020. PMID: 32220283 Clinical Trial.
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.
Medeiros-Ribeiro AC, Aikawa NE, Saad CGS, Yuki EFN, Pedrosa T, Fusco SRG, Rojo PT, Pereira RMR, Shinjo SK, Andrade DCO, Sampaio-Barros PD, Ribeiro CT, Deveza GBH, Martins VAO, Silva CA, Lopes MH, Duarte AJS, Antonangelo L, Sabino EC, Kallas EG, Pasoto SG, Bonfa E. Medeiros-Ribeiro AC, et al. Among authors: kallas eg. Nat Med. 2021 Oct;27(10):1744-1751. doi: 10.1038/s41591-021-01469-5. Epub 2021 Jul 30. Nat Med. 2021. PMID: 34331051 Clinical Trial.
Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus.
Yuki EFN, Borba EF, Pasoto SG, Seguro LP, Lopes M, Saad CGS, Medeiros-Ribeiro AC, Silva CA, de Andrade DCO, Kupa LVK, Betancourt L, Bertoglio I, Valim J, Hoff C, Formiga FFC, Pedrosa T, Kallas EG, Aikawa NE, Bonfa E. Yuki EFN, et al. Among authors: kallas eg. Arthritis Care Res (Hoboken). 2022 Apr;74(4):562-571. doi: 10.1002/acr.24824. Epub 2022 Mar 4. Arthritis Care Res (Hoboken). 2022. PMID: 34806342 Free PMC article. Clinical Trial.
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study.
Aikawa NE, Kupa LVK, Pasoto SG, Medeiros-Ribeiro AC, Yuki EFN, Saad CGS, Pedrosa T, Fuller R, Shinjo SK, Sampaio-Barros PD, Andrade DCO, Pereira RMR, Seguro LPC, Valim JML, Waridel F, Sartori AMC, Duarte AJS, Antonangelo L, Sabino EC, Menezes PR, Kallas EG, Silva CA, Bonfa E. Aikawa NE, et al. Among authors: kallas eg. Lancet Rheumatol. 2022 Feb;4(2):e113-e124. doi: 10.1016/S2665-9913(21)00327-1. Epub 2021 Dec 3. Lancet Rheumatol. 2022. PMID: 34901885 Free PMC article.
Genotype-specific features reduce the susceptibility of South American yellow fever virus strains to vaccine-induced antibodies.
Haslwanter D, Lasso G, Wec AZ, Furtado ND, Raphael LMS, Tse AL, Sun Y, Stransky S, Pedreño-Lopez N, Correia CA, Bornholdt ZA, Sakharkar M, Avelino-Silva VI, Moyer CL, Watkins DI, Kallas EG, Sidoli S, Walker LM, Bonaldo MC, Chandran K. Haslwanter D, et al. Among authors: kallas eg. Cell Host Microbe. 2022 Feb 9;30(2):248-259.e6. doi: 10.1016/j.chom.2021.12.009. Epub 2022 Jan 7. Cell Host Microbe. 2022. PMID: 34998466 Free PMC article.
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study.
Netto LC, Ibrahim KY, Picone CM, Alves APPS, Aniceto EV, Santiago MR, Parmejani PSS, Aikawa NE, Medeiros-Ribeiro AC, Pasoto SG, Yuki EFN, Saad CGS, Pedrosa T, Lara AN, Ceneviva C, Bonfa E, Kallas EG, Avelino-Silva VI. Netto LC, et al. Among authors: kallas eg. Lancet HIV. 2022 May;9(5):e323-e331. doi: 10.1016/S2352-3018(22)00033-9. Epub 2022 Mar 23. Lancet HIV. 2022. PMID: 35338835 Free PMC article.
Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients.
Silva CA, Medeiros-Ribeiro AC, Kupa LVK, Yuki EFN, Pasoto SG, Saad CGS, Fusco SRG, Pereira RMR, Shinjo SK, Halpern ASR, Borba EF, Souza FHC, Guedes LKN, Miossi R, Bonfiglioli KR, Domiciano DS, Shimabuco AY, Andrade DCO, Seguro LPC, Fuller R, Sampaio-Barros PD, Assad APL, Moraes JCB, Goldenstein-Schainberg C, Giardini HAM, Silva HC, Martins VAO, Villamarin LEB, Novellino RS, Sales LP, Araújo CSR, Silva MSR, Filho DMN, Lopes MH, Duarte AJS, Kallas EG, Aikawa NE, Bonfa E. Silva CA, et al. Among authors: kallas eg. Nat Commun. 2022 Oct 3;13(1):5801. doi: 10.1038/s41467-022-33042-0. Nat Commun. 2022. PMID: 36192386 Free PMC article.
273 results